Table 2 Most frequent (≥10% of patients) treatment-emergent adverse events of any grade in the safety population
TEAE | Overall (N = 97) | |
|---|---|---|
Any grade, n (%) | Grade ≥3, n (%) | |
Asthenia/fatigue | 56 (57.7) | 8 (8.2) |
Nausea | 41 (42.3) | 1 (1.0) |
Anemiaa | 35 (36.1) | 20 (20.6) |
Decreased appetite | 28 (28.9) | 2 (2.1) |
Thrombocytopeniab | 22 (22.7) | 11 (11.3) |
Vomiting | 22 (22.7) | 1 (1.0) |
Blood creatinine increased | 21 (21.6) | 1 (1.0) |
Constipation | 21 (21.6) | 3 (3.1) |
ALT/AST increased | 17 (17.5) | 5 (5.2) |
Dysgeusia | 16 (16.5) | 0 |
Dyspnea | 13 (13.4) | 3 (3.1) |
Weight decreased | 13 (13.4) | 0 |
Diarrhea | 12 (12.4) | 1 (1.0) |
Urinary tract infection | 12 (12.4) | 4 (4.1) |
Abdominal pain | 11 (11.3) | 1 (1.0) |
Hypophosphatemia | 10 (10.3) | 5 (5.2) |
Dehydration | 10 (10.3) | 2 (2.1) |
Insomnia | 10 (10.3) | 0 |
Pyrexia | 10 (10.3) | 1 (1.0) |